Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02481050
Title Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Eisai Inc.
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Facility #1 Denver Colorado 80218 United States Details
Facility #1 Columbia Maryland 21044 United States Details
Facility #1 Omaha Nebraska 68130 United States Details
Facility #1 Albany New York 12206 United States Details
Facility #1 Portland Oregon 97213 United States Details
Facility #1 Dallas Texas 75231 United States Details
Facility #2 Dallas Texas 75246 United States Details
Facility #1 Houston Texas 77024 United States Details
Facility #1 San Antonio Texas 78217 United States Details
Facility #1 Tyler Texas 75702 United States Details
Facility #1 Leesburg Virginia 20176 United States Details
Facility #1 Winchester Virginia 22601 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field